Afatinib Plus Vinorelbine Versus Trastuzumab Plus Vinorelbine in Patients With HER2-Overexpressing Metastatic Breast Cancer Who Had Progressed on One Previous Trastuzumab Treatment (LUX-Breast 1): An Open-Label, Randomised, Phase 3 Trial

Trastuzumab resistance is a key therapeutic challenge in metastatic breast cancer. We postulated that broader inhibition of ErbB receptors with afatinib would improve clinical outcomes compared with HER2 inhibition alone in patients who had progressed on previous trastuzumab treatment. LUX-Breast 1 compared afatinib plus vinorelbine with trastuzumab plus vinorelbine for such patients with HER2-positive metastatic breast cancer.

 The Lancet Oncology

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.